aaaa(Tewari et al., 2013, Kashyap and Hedau, 2012, Ptter et al., 2008, Alam et al.

,
2012, Ishibashi et al., 2011, Liao et al., 2015, Castle et al., 2014)

ALAM, M. S., ALI, A., MEHDI, S. J., ALYASIRI, N. S., KAZIM, Z., BATRA, S., MANDAL, A.
K., RIZVI, M. M. & ALAM 2012. HPV typing and its relation with apoptosis in
cervical carcinoma from Indian population. Tumor Biology, 33, 17-22.
CASTLE, P. E., QIAO, Y. L., ZHAO, F. H., CHEN, W., VALDEZ, M., ZHANG, X., KANG, L.
N., BANSIL, P., PAUL, P., BAI, P., PECK, R., LI, J., CHEN, F. & JERONIMO, J. 2014.
Clinical determinants of a positive visual inspection after treatment with
acetic acid for cervical cancer screening. BJOG: An International Journal Of
Obstetrics And Gynaecology, 121, 739-746.
ISHIBASHI, M., KISHINO, M., SATO, S., MORII, E., OGAWA, Y., AOZASA, K., KOGO, M. &
TOYOSAWA, S. 2011. The prevalence of human papillomavirus in oral
premalignant lesions and squamous cell carcinoma in comparison to cervical
lesions used as a positive control. International Journal of Clinical Oncology,
16, 646-53.
KASHYAP, V. & HEDAU, S. 2012. High-risk HPV-16 DNA testing after treatment for
carcinoma cervix. Indian Journal of Pathology and Microbiology, 55, 594-595.
LIAO, S., ZHANG, W., HU, X., WANG, W., DENG, D., WANG, H., WANG, C., ZHOU, J.,
WANG, S., ZHANG, H. & MA, D. 2015. A novel "priming-boosting" strategy for
immune interventions in cervical cancer. Molecular Immunology, 64, 295-305.
PTTER, R., KIRISITS, C., FIDAROVA, E. F., DIMOPOULOS, J. C. A., BERGER, D.,
TANDERUP, K. & LINDEGAARD, J. C. 2008. Present status and future of highprecision image guided adaptive brachytherapy for cervix carcinoma. Acta
Oncologica, 47, 1325-1336.
TEWARI, K. S., SILL, M., LONG, H. J., RAMONDETTA, L. M., LANDRUM, L. M., OAKNIN,
A., REID, T. J., LEITAO, M. M., MICHAEL, H. E. & MONK, B. J. Incorporation of
bevacizumab in the treatment of recurrent and metastatic cervical cancer: A
phase III randomized trial of the Gynecologic Oncology Group. ASCO Annual
Meeting Proceedings, 2013. 3.